VEGF Double Nickase Plasmid (h): sc-400019-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VEGF Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- VEGF Double Nickase Plasmid (h) and VEGF Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting VEGFA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VEGF Antibody (F-5): sc-365578
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VEGF Double Nickase Plasmid (h) | sc-400019-NIC | 20 µg | $410.00 | |||
VEGF Double Nickase Plasmid (h2) | sc-400019-NIC-2 | 20 µg | $410.00 |
VEGFA encodes vascular endothelial growth factor (VEGF), a secreted, heparin-binding cytokine that regulates endothelial cell proliferation, migration, and survival. VEGF signaling through VEGFR1/VEGFR2 activates PI3K–AKT, MAPK/ERK, and PLCγ–PKC pathways to coordinate angiogenesis, vascular permeability, and tissue remodeling under hypoxia and inflammatory cues. Dysregulated VEGFA expression or signaling is implicated in pathological neovascularization and vascular leakage observed across tumor microenvironments, ischemic injury responses, and retinal vascular disorders. As a central node in angiogenic signaling, VEGFA is widely used to study endothelial-stromal communication, extracellular matrix remodeling, and hypoxia-driven transcriptional programs.
VEGF Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the VEGFA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within VEGFA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt VEGFA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of VEGFA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.